BiotechTube
Home/Foghorn Therapeutics/Danette Daniels
DD

Danette Daniels

Vice President, Protein Degrader Platform

Foghorn Therapeutics

Therapeutic Areas

Oncology

Foghorn Therapeutics Pipeline

DrugIndicationPhase
FHD-286Relapsed/Refractory Acute Myeloid Leukemia (AML)Phase 1
FHD-609Synovial SarcomaPhase 1
FHD-909Indication TBD (BRM-selective inhibitor)Phase 1

Leadership Team at Foghorn Therapeutics

AG
Adrian Gottschalk
President and Chief Executive Officer
SB
Steven Bellon
Chief Scientific Officer
CC
Carlos Costa
Chief People Officer
View full Foghorn Therapeutics profile